Skip to main content
Premium Trial:

Request an Annual Quote

Enable Bio to Participate in NIH Program to Commercialize Technologies

NEW YORK (360Dx) – Enable Biosciences said on Tuesday that it has been selected to participate in a National Institutes of Health program to help small healthcare and life science companies bring their products to market.

The San Francisco-based company was chosen for the 2018-2019 National Institutes of Health Commercial Accelerator Program, which enables participants to build a market presence, establish relationships with customers, create commercial opportunities, and generate revenues, it said. Enable added that it plans to use the program to bring its technology, called Antibody Detection by Agglutination-PCR, or ADAP, for type 1 diabetes to market.

Earlier this year, JDRF, a global organization that funds type 1 diabetes research, awarded Stanford University researchers $700,000 to work with Enable to validate and expand the capability of the ADAP platform.

Last month, the company announced it received a Small Business Innovation Research Phase I grant of $223,806 to accelerate the development of its blood tests for food allergy.